In today’s session Shire PLC (ADR) (SHPG) registered an unusually high (3,269) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious SHPG increase. With 3,269 contracts traded and 2694 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: SHPG161216C00190000 closed last at: $1.7 or 8.1% down. About 590,812 shares traded hands. Shire PLC (ADR) (NASDAQ:SHPG) has declined 6.38% since April 21, 2016 and is downtrending. It has underperformed by 11.71% the S&P500.
Analysts await Shire PLC (ADR) (NASDAQ:SHPG) to report earnings on February, 9. They expect $3.26 EPS, up 9.76% or $0.29 from last year’s $2.97 per share. SHPG’s profit will be $966.60 million for 13.14 P/E if the $3.26 EPS becomes a reality. After $3.17 actual EPS reported by Shire PLC (ADR) for the previous quarter, Wall Street now forecasts 2.84% EPS growth.
Shire PLC (ADR) (NASDAQ:SHPG) Ratings Coverage
Out of 18 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 15 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 83% are positive. Shire plc (ADR) has been the topic of 28 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, October 27 by HSBC. The stock of Shire PLC (ADR) (NASDAQ:SHPG) earned “Buy” rating by Bank of America on Friday, January 15. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, May 26. Bryan Garnier & Cie initiated the shares of SHPG in a report on Monday, May 23 with “Buy” rating. As per Thursday, August 6, the company rating was downgraded by BNP Paribas. The rating was maintained by JP Morgan with “Overweight” on Friday, May 20. The firm earned “Outperform” rating on Tuesday, January 12 by Credit Suisse. The company was maintained on Monday, September 28 by RBC Capital Markets. The stock has “Buy” rating given by Liberum Capital on Friday, May 6. The stock of Shire PLC (ADR) (NASDAQ:SHPG) has “Buy” rating given on Tuesday, June 28 by Goldman Sachs.
According to Zacks Investment Research, “Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)”
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of $50.80 billion. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 64.48 P/E ratio.
SHPG Company Profile
Shire plc, incorporated on January 28, 2008, is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.
More recent Shire PLC (ADR) (NASDAQ:SHPG) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on July 12, 2012. Also Marketwatch.com published the news titled: “Shire PLC ADR NASDAQ: SHPG” on July 12, 2012. Businessfinancenews.com‘s news article titled: “Shire PLC (ADR) Future Now Rests On Xiidra” with publication date: July 12, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.